

Ref: FOI/GS/ID 5708

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

04 March 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Cancer Treatments.

You asked:

1a - How many melanoma patients undergoing treatment are BRAF+?

1b - In the past 3 months, how many melanoma patients were treated with the following:

Bevacizumab

Cobimetinib

Dabrafenib

Dabrafenib AND trametinib

Dacarbazine

Encorafenib AND binimetinib

Ipilimumab

Ipilimumab AND Nivolumab

Nivolumab

Pembrolizumab

Trametinib

Vemurafenib

Vemurafenib AND Cobimetinib

Other active systemic anti-cancer therapy

Palliative care

1c - In the past 3 months how many patients were seen who had stage III resectable melanoma

1d - Of all stage III patients seen, how many received a complete resection?

2 - In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:

Afatinib

Atezolizumab monotherapy

Bevacizumab

Docetaxel monotherapy
Durvalumab
Erlotinib
Gemcitabine
Necitumumab
Nivolumab
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy [please state]
Palliative care only
 3 - *In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:*
Afatinib
Alectinib
Atezolizumab mono
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Erlotinib
Gefitinib
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Other active systemic anti-cancer therapy [please state]
Palliative care only

Trust response:

1a. The Trust does not record BRAF+ status in a recordable format. In order to answer this question the Trust would need to manually check the individual patient notes. The Trust has estimated that it will cost more than the appropriate limit to consider this part of your request. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply

with this part of your request and we will not be processing this part of your request further.

1b. None

1c and 1d – The Trust does not provide a skin surgery service.

2. None

3.

Afatinib 4

Alectinib 0

Atezolizumab mono 0

Atezolizumab + bevacizumab + carboplatin + paclitaxel 1

Bevacizumab 0

Brigatinib 0

Ceritinib 1

Crizotinib 0

Dacomitinib 0

Docetaxel monotherapy 0

Erlotinib 0

Gefitinib 0

Nintedanib with docetaxel 0

Nivolumab 0

Osimertinib 1

Paclitaxel 0

Pembrolizumab monotherapy 1

Pembrolizumab chemo in combination 1

Pemetrexed with carboplatin 3

Pemetrexed with cisplatin 0

Ramucirumab 0

Other Systematic Anti_Cancer Therapy

Vinorelbine & Cisplatin 1

Durvalumab 1